Etomidate in the control of severe Cushing's syndrome by neuroendocrine carcinoma

Etomidate is a very effective drug in severe Cushing's syndrome that is refractory to ketoconazol. Control of the serum cortisol levels in ectopic Cushing's syndrome can be obtained with infusion rates much lower than those used in anesthesia, without respiratory side effects.

Detalles Bibliográficos
Autores principales: Reza‐Albarrán, Alfredo Adolfo, Andino Ríos, Gerson Geovany, Gómez Herrera, Laura Gabriela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930188/
https://www.ncbi.nlm.nih.gov/pubmed/29744071
http://dx.doi.org/10.1002/ccr3.1478
_version_ 1783319457130610688
author Reza‐Albarrán, Alfredo Adolfo
Andino Ríos, Gerson Geovany
Gómez Herrera, Laura Gabriela
author_facet Reza‐Albarrán, Alfredo Adolfo
Andino Ríos, Gerson Geovany
Gómez Herrera, Laura Gabriela
author_sort Reza‐Albarrán, Alfredo Adolfo
collection PubMed
description Etomidate is a very effective drug in severe Cushing's syndrome that is refractory to ketoconazol. Control of the serum cortisol levels in ectopic Cushing's syndrome can be obtained with infusion rates much lower than those used in anesthesia, without respiratory side effects.
format Online
Article
Text
id pubmed-5930188
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-59301882018-05-09 Etomidate in the control of severe Cushing's syndrome by neuroendocrine carcinoma Reza‐Albarrán, Alfredo Adolfo Andino Ríos, Gerson Geovany Gómez Herrera, Laura Gabriela Clin Case Rep Case Reports Etomidate is a very effective drug in severe Cushing's syndrome that is refractory to ketoconazol. Control of the serum cortisol levels in ectopic Cushing's syndrome can be obtained with infusion rates much lower than those used in anesthesia, without respiratory side effects. John Wiley and Sons Inc. 2018-03-12 /pmc/articles/PMC5930188/ /pubmed/29744071 http://dx.doi.org/10.1002/ccr3.1478 Text en © 2018 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Reza‐Albarrán, Alfredo Adolfo
Andino Ríos, Gerson Geovany
Gómez Herrera, Laura Gabriela
Etomidate in the control of severe Cushing's syndrome by neuroendocrine carcinoma
title Etomidate in the control of severe Cushing's syndrome by neuroendocrine carcinoma
title_full Etomidate in the control of severe Cushing's syndrome by neuroendocrine carcinoma
title_fullStr Etomidate in the control of severe Cushing's syndrome by neuroendocrine carcinoma
title_full_unstemmed Etomidate in the control of severe Cushing's syndrome by neuroendocrine carcinoma
title_short Etomidate in the control of severe Cushing's syndrome by neuroendocrine carcinoma
title_sort etomidate in the control of severe cushing's syndrome by neuroendocrine carcinoma
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930188/
https://www.ncbi.nlm.nih.gov/pubmed/29744071
http://dx.doi.org/10.1002/ccr3.1478
work_keys_str_mv AT rezaalbarranalfredoadolfo etomidateinthecontrolofseverecushingssyndromebyneuroendocrinecarcinoma
AT andinoriosgersongeovany etomidateinthecontrolofseverecushingssyndromebyneuroendocrinecarcinoma
AT gomezherreralauragabriela etomidateinthecontrolofseverecushingssyndromebyneuroendocrinecarcinoma

Ejemplares similares